Early disease detection: a collaborative approach
Global biopharmaceutical company UCB is investing £1 billion in research and development, including a new state-of-the-art facility, continuing the UK’s reputation as a world-leading base for global life sciences research and industry. The programme, backed by up to £79 million of government funding, will study five million healthy people in a bid to develop new diagnostic tests using artificial intelligence (AI).
This story is Premium Content and is only available to registered users. Please log in to view the full text. If you don't already have an account, please register with us completely free of charge.